Hematologic outcomes and blood utilization in cancer patients with chemotherapy-induced anemia (CIA) pre- and post-national coverage determination (NCD): results from a multicenter chart review.
Support Care Cancer., Sep;20(9):2089-96 (2012)
Carboplatin/pemetrexed/bevacizumab in the treatment of patients with advanced non-small-cell lung cancer: a single-institution experience.
Clin Lung Cancer., May;11(3):192-7 (2010)
The evolving role of histology in the management of advanced non-small-cell lung cancer.
J. Clin. Oncol., Dec;28(36):5311-20 (2010)
Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 patients with chemotherapy-naÃ¯ve advanced non-small cell lung cancer.
J Thorac Oncol., Jun;3(6):623-30 (2008)
Phase II study of paclitaxel, carboplatin, and cetuximab as first line treatment, for patients with advanced non-small cell lung cancer (NSCLC): results of OPN-017.
J Thorac Oncol., Nov;3(11):1286-92 (2008)
The 800-lb gorilla we all ignore: treatment of NSCLC in elderly and PS 2 patients.
Clin Adv Hematol Oncol., Mar;5(3):216-33 (2007)
Phase I study of radical thoracic radiation, weekly irinotecan, and cisplatin in locally advanced non-small cell lung carcinoma.
J Thorac Oncol., Mar;2(3):203-9 (2007)
Salvage therapy with vinorelbine in advanced non-small-cell lung cancer: a retrospective review of the Fox Chase Cancer Center experience and a review of the literature.
Clin Lung Cancer., Mar;8(5):319-26 (2007)
Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911.
J. Clin. Oncol., Oct;25(30):4800-5 (2007)
The emerging role of cetuximab in head and neck cancer: a 2007 perspective.
Cancer Invest., Feb;26(1):96-103 (2008)
Resectable non-small cell lung cancer in the elderly: is there a role for adjuvant treatment?
Drugs Aging., 25(3):209-18 (2008)
Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumors.
Am. J. Clin. Oncol., Feb;31(1):1-5 (2008)
Targeted therapy in head and neck cancer: state of the art 2007 and review of clinical applications.
Cancer., Jun;112(12):2635-45 (2008)
Cooperative group portfolio in locally advanced non-small-cell lung cancer: are we making progress?
Clin Lung Cancer., Mar;9(2):85-91 (2008)
Toxicity and outcome analysis of patients with recurrent head and neck cancer treated with hyperfractionated split-course reirradiation and concurrent cisplatin and paclitaxel chemotherapy from two prospective phase I and II studies.
Head Neck., May;27(5):406-14 (2005)
Phase I trial of concurrent hyperfractionated split course radiotherapy (HFx RT), cisplatin (cDDP), and paclitaxel in patients with recurrent, previously irradiated, or treatment-naÃ¯ve locally advanced upper aerodigestive malignancy.
Cancer Invest., Mar;24(2):164-73 (2006)
Patterns of care survey (PCS) in lung cancer: how well does current U.S. practice with chemotherapy in the non-metastatic setting follow the literature?
Lung Cancer., Apr;48(1):93-102 (2005)
Current management of brain metastases, with a focus on systemic options.
J. Clin. Oncol., Sep;23(25):6207-19 (2005)
The surgical management of superior sulcus tumors: a retrospective review with long-term follow-up.
Ann. Thorac. Surg., Apr;79(4):1174-9 (2005)
Role of zoledronic acid in the setting of bone metastases from non-small-cell lung cancer.
Clin Lung Cancer., Mar;6(5):314-6 (2005)